Richard Ko, DO
Pulmonary Disease · Columbus, OHNPI 1710061742
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $793 of the $938 with a category attached, or 84.5%. 7 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 39.4% of the total. Reporting peaked in 2024 at $397 and has fallen 89.1% since, to $43 in 2025. That places this record below the midpoint for pulmonary disease clinicians in OH, where the typical reported total is $1,293.
Across 42 payments — averaging $22.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$369
- Harmony Biosciences LLC$277
- Inspire Medical Systems, Inc.$98
- Avadel CNS Pharmaceuticals, LLC$69
- Itamar Medical Inc$59
- Idorsia Pharmaceuticals US Inc$45
- plus $21 from 1 others
What the payments were for
- Food & beverage$79385%
- Education$14515%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 16 | $369 |
| Harmony Biosciences LLC | 11 | $277 |
| Inspire Medical Systems, Inc. | 4 | $98 |
| Avadel CNS Pharmaceuticals, LLC | 4 | $69 |
| Itamar Medical Inc | 3 | $59 |
| Idorsia Pharmaceuticals US Inc | 3 | $45 |
| 3b Medical, Inc. | 1 | $21 |
How this compares
$938 in reported general payments places this provider in the 40th percentile of 571 pulmonary disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuvigilArmodafinil | 11 | $11,311 |
| Armodafinil | 30 | $2,474 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 23 | $1,711 |
| Modafinil | 40 | $1,020 |
| Clonazepam | 30 | $396 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 15 | $265 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 34 | $244 |
| Fluticasone Propionate | 12 | $157 |
| Gabapentin | 36 | $135 |
| Zolpidem Tartrate | 15 | $72 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Columbus
- Christian GhattasColumbus$286K
- Alberto ReveloColumbus$202K
- James FaganColumbus$179K
- Jeffrey HorowitzColumbus$31K
- Ehab HusseinColumbus$25K
- Joseph KhabbazaAkron$655K
- Robert BaughmanCincinnati$640K
- Kristin HighlandCleveland$551K
- Bruce CorserCincinnati$502K
- Jason StieneckerLima$397K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.